The deal adds to a growing streak of partnerships involving new types of T cell engagers and gives Vertex another chance to broaden a business still reliant on cystic fibrosis medicines.
An article from
The deal adds to a growing streak of partnerships involving new types of T cell engagers and gives Vertex another chance to broaden a business still reliant on cystic fibrosis medicines.
Published July 29, 2026
Vertex formed a partnership with AbCellera on July 29, 2026.
Permission granted by Vertex Pharmaceuticals
The potentially $4 billion collaboration is the latest example of drugmakers working to broaden the use of T cell engagers,…
AbCellera and Jazz Pharmaceuticals strike a preclinical T cell engager deal worth up to $4.1B targeting gastrointestinal and…
Vertex Pharmaceuticals has struck a $10 billion deal—its largest ever—to acquire | Vertex Pharmaceuticals has struck a $10…
Atea's BEM/RZR matches Gilead's Epclusa in Phase 3; AbCellera partners with Vertex for $28M; LB Pharma raises $150M for…
Vertex's Casgevy wins pediatric approval, United Therapeutics buys Thymmune for up to $300M, plus deals from Insilico, Fosun and…
By acquiring Crinetics Pharmaceuticals, Vertex is staking its place alongside other big biotechs such as Gilead, Regeneron and…
